Jul 1, 2025 08:31AM Oragenics (OGEN) Prices $20M Offering

May 28, 2025 07:00AM Oragenics (OGEN) Announces 1-for-30 Reverse Stock Split

May 13, 2025 08:31AM Oragenics (OGEN) Approved to Initiate Phase II Concussion Drug Trial in Australia

Mar 27, 2025 08:33AM Oragenics (OGEN) Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 6, 2025 09:30AM Oragenics (OGEN) Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002

Feb 11, 2025 08:32AM Oragenics (OGEN) Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Jan 21, 2025 08:16AM Oragenics (OGEN) Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Dec 16, 2024 08:10AM Oragenics (OGEN) Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oct 9, 2024 07:30AM Oragenics (OGEN) Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Sep 4, 2024 08:37AM Oragenics (OGEN) Prices 8.1M Share Offering at $0.55/sh

Aug 16, 2024 04:49PM Oragenics (OGEN) Files for 2.4M Share and Warrant Offering

Aug 16, 2024 04:31PM Oragenics (OGEN) Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 12, 2024 08:31AM Oragenics (OGEN) Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 8, 2024 08:45AM Oragenics (OGEN) Announces ONP-002 Successfully Clears FDA-Required Cardiotoxicity Testing

Jul 10, 2024 08:07AM Oragenics (OGEN) Improves Intranasal Drug Formulation for Treating Concussed Patients

Jun 27, 2024 08:32AM Oragenics (OGEN) Develops Automated Intranasal Device for Treating Concussed Patients

Jun 25, 2024 08:31AM Oragenics (OGEN) Prices 1.1M Share Offering at $1/sh

Jun 25, 2024 05:48AM Oragenics (OGEN) Announces Proposed Share Offering

Jun 20, 2024 08:04AM Oragenics (OGEN) Announces NYSE American Acceptance of Plan of Compliance